EGFR and neoplasm: Therefore, we believe that this therapeutic approach, following complete or cytoreductive resection of GBM, could lead to (i) elimination of residual or surgically inaccessible EGFR+ve cancer cells and (ii) subsequent stimulation of anti-tumour immunity.